-
Posted by
Two Blokes Jun 18 -
Filed in
Stock
-
4 views
Eli Lilly's $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine. The pharmaceutical behemoth paid a substantial premium of approximately 113% above Verve's 30-day volume-weighted average trading price, triggering an 80% surge in Verve's stock price on June 17, 2025.
